Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery

Yonsei University74 enrolled

Overview

The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.

Study Type

INTERVENTIONAL

Enrollment

Conditions

Cardiac Surgery

Interventions

rhEPODRUG

recombinant human erythropoietin(rhEPO)

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The 90 patients who are planned to have the heart surgery during this study period.(minimum age 20) Exclusion Criteria: * Uncontrolled hypertension(diastolic blood pressure(DBP)\>100 mmHg), Hct \> 45%, Plt. count)\>450,000 * There are no history of seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis. * No pregnancy, acute hyper parathyroidism.

Locations (1)

Severance hospital

Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.